The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis

Schmitt H, Billmeier U, Ulmschneider J, Admyre C, Knittel T, Zargari A, Neurath M, Atreya R (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Journal of Crohns & Colitis Elsevier

Book Volume: 12

Pages Range: S3-S4

DOI: 10.1093/ecco-jcc/jjx180.003

Authors with CRIS profile

Markus Neurath Lehrstuhl für Innere Medizin I Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

InDex Pharmaceuticals SE Sweden (SE)

How to cite

APA:

Schmitt, H., Billmeier, U., Ulmschneider, J., Admyre, C., Knittel, T., Zargari, A.,... Atreya, R. (2018). The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis. (pp. S3-S4).

MLA:

Schmitt, H., et al. "The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis." 2018. S3-S4.

BibTeX: Download